glp-1 not injected receptor agonists GLP-1 Injection Above Belly Button:

A critical exploration of the body positive movement within physical cultures taking an intersectionality approach

FDA prescribing information for some GLP-1 receptor agonists advises considering discontinuation for sustained increases in resting heart rate

For patients undergoing colonoscopy, who were on clear liquid diets the day prior, no clinically significant residual gastric volume was found in either group

The LEADER, REWIND, and SUSTAIN-6 trials of respective liraglutide 1.8 mg/daily (or maximum tolerated dose), once-weekly dulaglutide 1.5 mg, and once-weekly semaglutide 0.5 mg or 1.0 mg administration in patients with type 2 diabetes and cardiovascular disease or risk factors found decreased hazard ratios ranging from 0.74 to 0.88 for the primary composite endpoint first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke [112114]

Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan

GLP-1 access, coaching, navigation, screening, and engagement each addressed an important piece of the patient journey